Pubblicazioni

Proprotein convertase Subtilisin-Kexin type 9 (PCSK9) inhibitors and cardiovascular risk: does a further analysis of the fourier trial suggest changes in the target of lipid lowering therapy?

2018 - HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION
Cervelli, Nazzareno; Tocci, Giuliano; Ferri, Claudio

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma